Publications by authors named "O Fernandez-Calvo"
Introduction: The COVID-19 pandemic is a great burden worldwide, but its impact on patients with genitourinary cancer (GUC) is poorly characterized. This study aimed to characterize the clinical features and evolution of GUC patients affected by COVID-19 in Spain.
Patients And Methods: SOGUG-COVID-19 was an observational ambispective non-interventional study that recruited patients with SARS-CoV-2 infection who had been treated for GUC in 32 Spanish hospitals.
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of Lu-PSMA-617 radioligand-therapy in prostate cancer.
Clin Transl Oncol
September 2024
Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [Ga] and [F].
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how specific immune cell types in blood samples from patients with metastatic castration-resistant prostate cancer (mCRPC) can affect survival rates.
- Researchers analyzed pre-treatment blood samples from 152 patients and found that lower CD8 T-cell counts and higher monocyte levels were linked to shorter survival.
- Their results suggest that these immune cell types could act as important biomarkers for mCRPC management, supporting the need for further research in clinical trials.
Introduction: Radium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study, we aimed to ambispectively analyze overall survival (OS) and prognostic features in mCRPC in patients receiving Ra-223 as per clinical routine practice and identify the most suitable treatment sequence.
Patients And Methods: This study is observational, multicentric, and ambispective.
Article Synopsis
- The study investigates the long-term outcomes of patients with metastatic renal cell carcinoma who achieved a complete response to the TKI sunitinib, revealing little known prior information about this group.
- Data was collected from a registry of 62 patients treated in Spain between 2007 and 2018, with most patients having clear cell histology and previously undergoing nephrectomy.
- Results show that 75% of patients maintained complete response status after 10 years, indicating durable responses across different prognosis groups and metastasis sites.